Keyphrases
Phosphodiesterase Inhibitors
100%
Alzheimer's Disease
100%
Phase III Clinical Trial
100%
Phase II Clinical Trial
100%
Mild Cognitive Impairment
50%
Tolerability
16%
Expert Opinion
16%
Cognitive Processes
16%
Adverse Effects
16%
Age-related Cognitive Impairment
16%
Signaling Pathway
16%
Healthy Elderly
16%
Neuroprotection
16%
Procognitive
16%
Cyclic GMP
16%
Phosphodiesterase
16%
PDE4 Inhibitor
16%
Brain Circuits
16%
Neuroprotective Effect
16%
Cyclic Adenosine Monophosphate (cAMP)
16%
Phosphodiesterase 3 (PDE3)
16%
Cilostazol
16%
PDE9 Inhibitor
16%
Roflumilast
16%
Alzheimer's Disease Patient
16%
Area Cover
16%
Age-associated
16%
Prodromal Stage
16%
INIS
clinical trials
100%
phosphodiesterases
100%
nervous system diseases
100%
patients
71%
populations
28%
data
14%
doses
14%
increasing
14%
safety
14%
brain
14%
reviews
14%
animals
14%
drawing
14%
guanosine
14%
cyclic adenosine monophosphate
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Alzheimer's Disease
100%
Phosphodiesterase Inhibitor
100%
Clinical Study
42%
Mild Cognitive Impairment
42%
Phosphodiesterase
14%
Tolerability
14%
Memory Disorder
14%
Phosphodiesterase IV Inhibitor
14%
Cyclic AMP
14%
Cyclic GMP
14%
Phosphodiesterase III
14%
Neuroprotective Agent
14%
Neuroprotection
14%
Roflumilast
14%
Cilostazol
14%